Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
21.69
+1.42 (7.01%)
At close: Dec 5, 2025, 4:00 PM EST
21.90
+0.21 (0.97%)
After-hours: Dec 5, 2025, 7:59 PM EST
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 22.2, with a low estimate of 15 and a high estimate of 27. The average target predicts an increase of 2.35% from the current stock price of 21.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 5 | 5 |
| Hold | 8 | 8 | 8 | 8 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | -12.40% | Nov 28, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +24.48% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $23 | Buy | Maintains | $26 → $23 | +6.04% | Nov 11, 2025 |
| Wedbush | Wedbush | Hold Maintains $15 → $16 | Hold | Maintains | $15 → $16 | -26.23% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | -7.79% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
247.66M
from 3.55M
Increased by 6,876.34%
Revenue Next Year
8.02M
from 247.66M
Decreased by -96.76%
EPS This Year
2.18
from -5.00
EPS Next Year
-3.55
from 2.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 266.4M | 47.3M | ||||
| Avg | 247.7M | 8.0M | ||||
| Low | 215.6M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7,403.1% | -80.9% | ||||
| Avg | 6,876.3% | -96.8% | ||||
| Low | 5,973.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.81 | -0.78 | ||||
| Avg | 2.18 | -3.55 | ||||
| Low | 1.06 | -4.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.